Zhaohui Su, VP, Strategic Consulting at Veristat, shared a post on LinkedIn:
“As clinical trials become more complex, with smaller populations, innovative designs, and richer data sources, an integrated biometrics approach offers a strong foundation for generating robust, actionable insights.
This insightful e-book by Veristat on the evolving role of biometrics in clinical trials reinforced a positive trend. Biostatistics, data management, and statistical programming are increasingly functioning as a fully integrated scientific discipline, influencing not only how we analyze data but also how we design and execute trials.
Key takeaways include:
– End-to-end integration is becoming the norm: Biometrics now spans the full clinical development lifecycle, from study design and regulatory strategy to interim analyses and submission, ensuring that trials are both scientifically rigorous and decision-ready.
– Advances in data processes are improving trial efficiency: Real-time data validation, standardized structures, and closer cross-functional alignment are reducing delays historically driven by data quality issues.
– Statistical innovation is enabling better decision-making: Adaptive designs and more advanced analytical approaches allow studies to be more flexible, informative, and efficient while maintaining rigor.
– Stronger alignment with global regulatory standards (ICH E6/E9, CDISC, electronic data integrity requirements) is streamlining submissions and improving the consistency of evidence generation across regions.
These developments are not just about operational efficiency. They are enhancing the quality, interpretability, and credibility of clinical evidence. It is encouraging to see how methodological rigor and operational integration are converging to support more confident and timely decision-making in clinical development.”
e-book avaiable here.
Other articles featuring Zhaohui Su on OncoDaily.